Molbio Diagnostics Ltd
Molbio Diagnostics is an innovative point-
of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within
an hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care.
Through its wholly owned subsidiary,
Bigtec Labs, Molbio has strong research
and development capabilities focused on creating diagnostic platforms for point-of-
care (POC) testing. From product development to large-scale deployment, the company aims
to improve access to reliable and affordable healthcare for everyone.
https://www.molbiodiagnostics.com/wp-content/uploads/2026/08/Molbio-Diagnostics-Limited-Red-Herring-Prospectus.pdf#page=215 #}
- Market Cap ₹ 16,574 Cr.
- Current Price ₹ 1,438
- High / Low ₹ 1,687 / 926
- Stock P/E 76.4
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 22.0 %
- ROE 14.8 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Debtor days have improved from 108 to 63.3 days.
- Company's working capital requirements have reduced from 169 days to 114 days
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 1,271 | 776 | 327 | 756 | 971 | 1,313 | |
| 676 | 457 | 286 | 552 | 746 | 1,062 | |
| Operating Profit | 595 | 319 | 40 | 204 | 226 | 252 |
| OPM % | 47% | 41% | 12% | 27% | 23% | 19% |
| 1 | 5 | 8 | -21 | -2 | 5 | |
| Interest | 35 | 25 | 6 | 8 | 9 | 23 |
| Depreciation | 12 | 42 | 19 | 24 | 26 | 36 |
| Profit before tax | 549 | 258 | 23 | 152 | 188 | 198 |
| Tax % | 25% | 27% | 32% | 27% | 26% | 27% |
| 410 | 187 | 16 | 111 | 140 | 145 | |
| EPS in Rs | 2,027.06 | 833.37 | 69.00 | 493.01 | 62.00 | 12.83 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | 59% |
| TTM: | 35% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -19% |
| 3 Years: | 111% |
| TTM: | 1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 16% |
| Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | |
| Reserves | 333 | 681 | 737 | 848 | 988 | |
| 257 | 105 | 57 | 70 | 26 | ||
| 215 | 85 | 123 | 157 | 291 | ||
| Total Liabilities | 806 | 874 | 920 | 1,077 | 1,307 | |
| 55 | 182 | 189 | 209 | 215 | ||
| CWIP | 100 | 0 | 0 | 2 | 18 | |
| Investments | 9 | 9 | 54 | 54 | 95 | |
| 643 | 683 | 676 | 813 | 980 | ||
| Total Assets | 806 | 874 | 920 | 1,077 | 1,307 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 344 | 98 | 68 | 38 | 249 | ||
| -142 | -87 | -51 | -31 | -98 | ||
| -192 | -20 | 31 | -24 | -17 | ||
| Net Cash Flow | 10 | -9 | 48 | -18 | 133 | |
| Free Cash Flow | 212 | 35 | 55 | 24 | 206 | |
| CFO/OP | 78% | 53% | 251% | 39% | 139% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 61 | 113 | 194 | 174 | 86 | |
| Inventory Days | 261 | 402 | 885 | 393 | 395 | |
| Days Payable | 124 | 64 | 201 | 129 | 226 | |
| Cash Conversion Cycle | 198 | 450 | 877 | 438 | 254 | |
| Working Capital Days | 75 | 206 | 479 | 239 | 155 | |
| ROCE % | 41% | 4% | 22% | 21% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Pursuant to Regulation 30 of the SEBI(LODR),2015, Please find attached herewith the Transcripts of the Earning call held on September 08,2026 in relation to the …
-
Change Of Corporate Identification Number (CIN) Of The Company.
- Molbio Diagnostics’ CIN changed to L33125GA2000PLC002909; MCA status updated to listed after NSE/BSE listing.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording of Q1 FY2027 earnings call is available on Molbio’s website.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Investor Presentation on Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper advertisments of Un-Audited Financials Results for the quarter ended June 30, 2026.
Concalls
-
Sep 2026Transcript PPT REC